Key result
Thrombolytic therapy review weighs risks and benefits in submassive PE to identify patients facing clinical deterioration.
Why the study?
Does thrombolytic therapy benefit patients with submassive pulmonary embolism?
Does thrombolytic therapy benefit patients with submassive pulmonary embolism?
This review discusses the risks and benefits of thrombolytic therapy in submassive pulmonary embolism to help identify patients who may benefit from this treatment.
May inform case-by-case thrombolysis decisions in submassive PE; leaves open validated criteria for deterioration risk.
Despite growing interest in thrombolytic agents to treat submassive pulmonary embolism, their role in this scenario remains controversial. Needed is a way to identify patients with this condition who are at risk of clinical deterioration and who would benefit from thrombolytic therapy. Here, we review the use of thrombolytic agents in submassive pulmonary embolism to help distinguish the risk and benefits of this therapy.
No takes yet. Share an insight, caveat, or question.
Ataya et al. (2016) conducted a review in submassive pulmonary embolism. thrombolytic therapy was evaluated. Thrombolytic therapy for submassive pulmonary embolism is reviewed to help distinguish its risks and benefits and identify patients at risk of clinical deterioration.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: